IFN-beta pharmacogenomics in multiple sclerosis.

abstract：AIM:Pharmacogenomics could play a role in improving patient care, reducing adverse drug reactions and overall healthcare costs. However, whether it is utilized may be determined by how it is perceived by healthcare professionals, including pharmacists. METHODS:A cross-sectional web-based survey evaluated psychiatric p...

journal_title：Pharmacogenomics

authors： Shishko I,Almeida K,Silvia RJ,Tataronis GR

更新日期：2015-01-01 00:00:00

abstract：:Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...

journal_title：Pharmacogenomics

authors： Phillips KA,Van Bebber SL

更新日期：2004-12-01 00:00:00

abstract：UNLABELLED:Warfarin, a widely prescribed oral anticoagulant, is used for the prevention of thromboembolism. Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements. However, it is likely that other genes could also affect warfarin dose. AIMS:In this study, we aimed to identi...

journal_title：Pharmacogenomics

authors： Lee MT,Chen CH,Chou CH,Lu LS,Chuang HP,Chen YT,Saleem AN,Wen MS,Chen JJ,Wu JY,Chen YT

更新日期：2009-12-01 00:00:00

abstract：:Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

journal_title：Pharmacogenomics

authors： Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

更新日期：2021-01-01 00:00:00

abstract：:Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

journal_title：Pharmacogenomics

authors： Sardu C,Santamaria M,Paolisso G,Marfella R

更新日期：2015-11-01 00:00:00

abstract：:Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the p...

journal_title：Pharmacogenomics

authors： Chen M,Hu C,Jia W

更新日期：2015-01-01 00:00:00

abstract：:The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...

journal_title：Pharmacogenomics

authors： Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

更新日期：2004-10-01 00:00:00

abstract：:Migraine is considered one of the most disabling neurological disorder with a high socioeconomic burden. Pharmacological management includes many classes of drugs which in the most cases, are administrated in polytherapy. The therapeutic scheme of migraineurs is often affected by comorbidities which need concomitant m...

journal_title：Pharmacogenomics

authors： Borro M,Guglielmetti M,Simmaco M,Martelletti P,Gentile G

更新日期：2019-11-01 00:00:00

abstract：:Childhood acute lymphoblastic leukemia survival rates have increased remarkably during last decades due, in part, to intensive treatment protocols. However, therapy resistance and toxicity are still two important barriers to survival. In this context, pharmacoepigenetics arises as a tool to identify new predictive mar...

journal_title：Pharmacogenomics

authors： Umerez M,Garcia-Obregon S,Martin-Guerrero I,Astigarraga I,Gutierrez-Camino A,Garcia-Orad A

更新日期：2018-03-01 00:00:00

abstract：AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

journal_title：Pharmacogenomics

authors： Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

更新日期：2014-01-01 00:00:00

abstract：AIMS: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS & METHODS:Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. RESULTS:Carriers o...

journal_title：Pharmacogenomics

authors： Saab R,Zouk AN,Mastouri R,Skaar TC,Philips S,Kreutz RP

更新日期：2015-11-01 00:00:00

abstract：:Toxicogenomics is, arguably, the most exciting endeavor to better understand and/or predict the toxicity of drugs during their development, using technologies such as gene-expression microarrays. Through much of its (sometimes overzealous) build-up, toxicogenomics has found a natural niche as a bioinformatics and/or p...

journal_title：Pharmacogenomics

authors： Wills Q

更新日期：2007-08-01 00:00:00

abstract：:Related to many drug gene-product interactions, application of pharmacogenomics can lead to improved medication efficacy while decreasing or avoiding adverse drug reactions. However, utilizing pharmacogenomics without other information does not allow for optimal medication therapy. Currently, there is a lack of docume...

journal_title：Pharmacogenomics

authors： Smith TR,Kearney E,Hulick PJ,Kisor DF

更新日期：2016-05-01 00:00:00

abstract：OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

journal_title：Pharmacogenomics

authors： Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

更新日期：2007-12-01 00:00:00

abstract：BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...

journal_title：Pharmacogenomics

authors： Mitropoulou C,Fragoulakis V,Bozina N,Vozikis A,Supe S,Bozina T,Poljakovic Z,van Schaik RH,Patrinos GP

更新日期：2015-01-01 00:00:00

abstract：:Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...

journal_title：Pharmacogenomics

authors： Ferrell PB Jr,McLeod HL

更新日期：2008-10-01 00:00:00

abstract：AIM:This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. PATIENTS & METHODS:In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. RESULT...

journal_title：Pharmacogenomics

authors： Sim S,Bergh J,Hellström M,Hatschek T,Xie H

更新日期：2018-11-01 00:00:00

abstract：:Pharmacogenomics (PGx) implementation in clinical practice is steadily increasing. PGx uses genetic information to personalize medication use, which increases medication efficacy and decreases side effects. The availability of clinical PGx guidelines is essential for its implementation in clinical settings. Currently,...

journal_title：Pharmacogenomics

authors： Nagy M,Attya M,Patrinos GP

更新日期：2020-11-01 00:00:00

abstract：AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...

journal_title：Pharmacogenomics

authors： Karaca S,Bozkurt NC,Cesuroglu T,Karaca M,Bozkurt M,Eskioglu E,Polimanti R

更新日期：2015-01-01 00:00:00

abstract：AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...

journal_title：Pharmacogenomics

authors： Choi B,Kim MG,Han N,Kim T,Ji E,Park S,Kim IW,Oh JM

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects. Little is known about the long-term effects of GCs on gene-expression in vivo during inflammation. AIM:Identify gene signatures underlying prednisolone-induced metabolic side effects in a co...

journal_title：Pharmacogenomics

authors： Ellero-Simatos S,Fleuren WW,Bauerschmidt S,Dokter WH,Toonen EJ

更新日期：2014-04-01 00:00:00

abstract：AIM:Genetic variants contribute to statins' therapeutic variability. SREBF-SCAP pathway is a key player in lipid homeostasis. Hence, effect of SREBF-SCAP polymorphisms on therapeutic response was studied. PATIENTS & METHODS:Metabolic syndrome patients of either sex were prescribed rosuvastatin 10 mg for 24 weeks. Clin...

journal_title：Pharmacogenomics

authors： Rafeeq MM,Habib HS,Murad HAS,Gari MA,Gazzaz ZJ

更新日期：2018-02-01 00:00:00

abstract：:High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients...

journal_title：Pharmacogenomics

authors： Aghabozorg Afjeh SS,Shams J,Hamednia S,Boshehri B,Olfat A,Omrani MD

更新日期：2020-09-01 00:00:00

abstract：:While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

journal_title：Pharmacogenomics

authors： Narasimhan S,Lohoff FW

更新日期：2012-03-01 00:00:00

abstract：:The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the 'content problem', arising from the uncertainty of which molecules to focus on. The human cluster of dif...

journal_title：Pharmacogenomics

authors： Woolfson A,Ellmark P,Chrisp JS,A Scott M,Christopherson RI

更新日期：2006-07-01 00:00:00

abstract：:Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumar...

journal_title：Pharmacogenomics

authors： Voora D,McLeod HL,Eby C,Gage BF

更新日期：2005-07-01 00:00:00

abstract：UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...

journal_title：Pharmacogenomics

authors： Funke S,Timofeeva M,Risch A,Hoffmeister M,Stegmaier C,Seiler CM,Brenner H,Chang-Claude J

更新日期：2010-01-01 00:00:00

abstract：AIM:Gemcitabine is the first chemotherapeutic agent to show clinical benefits in pancreatic cancer patients. While interindividual variability in chemoresponse is observed, genetic factors that affect drug metabolism have not been clearly defined. The purpose of this study is to evaluate the relationships between genet...

journal_title：Pharmacogenomics

authors： Woo HI,Kim KK,Choi H,Kim S,Jang KT,Yi JH,Park YS,Park JO,Lee SY

更新日期：2012-07-01 00:00:00

abstract：:PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of s...

journal_title：Pharmacogenomics

authors： Kim DS,Marsillach J,Furlong CE,Jarvik GP

更新日期：2013-09-01 00:00:00

abstract：:Large differences are observed in chemotherapy response between breast cancer patients, with a substantial part of this variability being explained by genetic factors. Polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets influence the pharmacokinetics and pharmacodynamics of th...

journal_title：Pharmacogenomics

authors： González-Neira A

更新日期：2012-04-01 00:00:00